Jan 29 (Reuters) - Scholar Rock Holding Corp SRRK.O:
SCHOLAR ROCK SUBMITS BIOLOGICS LICENSE APPLICATION $(BLA.AU)$ TO THE U.S. FDA FOR APITEGROMAB AS A TREATMENT FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
SCHOLAR ROCK HOLDING CORP - TO SUBMIT MAA TO EMA IN 1Q 2025
SCHOLAR ROCK HOLDING CORP - REQUESTS PRIORITY REVIEW FOR APITEGROMAB
Source text: ID:nBw80d9q0a
Further company coverage: SRRK.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.